185 related articles for article (PubMed ID: 37506981)
1. Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology-KROG/RTOG 1119 Phase 2 Randomized Trial.
Kim IA; Winter KA; Sperduto PW; De Los Santos JF; Peereboom DM; Ogunleye T; Boulter D; Fritz JM; Cho KH; Shin KH; Zoberi I; Choi S; Palmer JD; Liem B; Kim YB; Anderson BM; Thakrar AW; Muanza TM; Kim MM; Choi DH; Mehta MP; White JR
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1391-1401. PubMed ID: 37506981
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
Kim JM; Miller JA; Kotecha R; Chao ST; Ahluwalia MS; Peereboom DM; Mohammadi AM; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Abraham J; Moore H; Budd GT; Suh JH
Neuro Oncol; 2019 May; 21(5):659-668. PubMed ID: 30726965
[TBL] [Abstract][Full Text] [Related]
4. Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Yomo S; Hayashi M; Cho N
J Neurooncol; 2013 Apr; 112(2):199-207. PubMed ID: 23296546
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
Lin NU; Freedman RA; Ramakrishna N; Younger J; Storniolo AM; Bellon JR; Come SE; Gelman RS; Harris GJ; Henderson MA; Macdonald SM; Mahadevan A; Eisenberg E; Ligibel JA; Mayer EL; Moy B; Eichler AF; Winer EP
Breast Cancer Res Treat; 2013 Nov; 142(2):405-14. PubMed ID: 24197661
[TBL] [Abstract][Full Text] [Related]
6. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
7. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Sperduto PW; Wang M; Robins HI; Schell MC; Werner-Wasik M; Komaki R; Souhami L; Buyyounouski MK; Khuntia D; Demas W; Shah SA; Nedzi LA; Perry G; Suh JH; Mehta MP
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1312-8. PubMed ID: 23391814
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis.
Khan M; Zhao Z; Arooj S; Zheng T; Liao G
Front Oncol; 2020; 10():576926. PubMed ID: 33240815
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.
Aoyama H; Shirato H; Tago M; Nakagawa K; Toyoda T; Hatano K; Kenjyo M; Oya N; Hirota S; Shioura H; Kunieda E; Inomata T; Hayakawa K; Katoh N; Kobashi G
JAMA; 2006 Jun; 295(21):2483-91. PubMed ID: 16757720
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy.
Mix M; Elmarzouky R; O'Connor T; Plunkett R; Prasad D
J Neurosurg; 2016 Dec; 125(Suppl 1):26-30. PubMed ID: 27903186
[TBL] [Abstract][Full Text] [Related]
12. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Shawky H; Tawfik H
J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
[TBL] [Abstract][Full Text] [Related]
13. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.
Patil CG; Pricola K; Sarmiento JM; Garg SK; Bryant A; Black KL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD006121. PubMed ID: 28945270
[TBL] [Abstract][Full Text] [Related]
14. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.
Brown PD; Jaeckle K; Ballman KV; Farace E; Cerhan JH; Anderson SK; Carrero XW; Barker FG; Deming R; Burri SH; Ménard C; Chung C; Stieber VW; Pollock BE; Galanis E; Buckner JC; Asher AL
JAMA; 2016 Jul; 316(4):401-409. PubMed ID: 27458945
[TBL] [Abstract][Full Text] [Related]
15. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.
Patil CG; Pricola K; Sarmiento JM; Garg SK; Bryant A; Black KL
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006121. PubMed ID: 22972090
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Bachelot T; Romieu G; Campone M; Diéras V; Cropet C; Dalenc F; Jimenez M; Le Rhun E; Pierga JY; Gonçalves A; Leheurteur M; Domont J; Gutierrez M; Curé H; Ferrero JM; Labbe-Devilliers C
Lancet Oncol; 2013 Jan; 14(1):64-71. PubMed ID: 23122784
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial.
Aoyama H; Tago M; Shirato H;
JAMA Oncol; 2015 Jul; 1(4):457-64. PubMed ID: 26181254
[TBL] [Abstract][Full Text] [Related]
19. Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy.
Chen L; Shen C; Redmond KJ; Page BR; Kummerlowe M; Mcnutt T; Bettegowda C; Rigamonti D; Lim M; Kleinberg L
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):939-947. PubMed ID: 28602418
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
Cao KI; Lebas N; Gerber S; Levy C; Le Scodan R; Bourgier C; Pierga JY; Gobillion A; Savignoni A; Kirova YM
Ann Oncol; 2015 Jan; 26(1):89-94. PubMed ID: 25355723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
